 |
Journal articles
Changes in Gut Microbiota by Chronic Stress Impair the Efficacy of Fluoxetine
Abstract : Major depressive disorders (MDDs) constitute a leading cause of disability worldwide and current pharmacological treatments are partially effective. The gut microbiota (GM) has recently emerged as a target of therapeutic interest for MDDs. In this study, we transfer GM from mice that sustained unpredictable chronic mild stress (UCMS) to healthy recipient mice. The fecal transfer induces despair-like behavior, decreases neurogenesis in the hippocampus (HpC), and impairs the antidepressant and neurogenic effects of a standard selective serotonin (5-HT) reuptake inhibitor, fluoxetine (FLX). These effects are paralleled by deficits in 5-HT bioavailability, biosynthesis, and reuptake in the HpC. Treatment with 5-hydroxytryptophan restores the levels of 5-HT and its precursors in the HpC, improves HpC neurogenesis, and alleviates despair-like symptoms. Our results reveal that stress-induced changes in GM are involved in the pathogenesis of depressive disorders and minimize FLX efficacy via alterations in the serotonergic pathway of Trp metabolism.
https://hal-pasteur.archives-ouvertes.fr/pasteur-03257987
Contributor : Bérengère Hugot Connect in order to contact the contributor
Submitted on : Friday, June 11, 2021 - 11:30:06 AM
Last modification on : Thursday, April 7, 2022 - 10:10:39 AM
Contributor : Bérengère Hugot Connect in order to contact the contributor
Submitted on : Friday, June 11, 2021 - 11:30:06 AM
Last modification on : Thursday, April 7, 2022 - 10:10:39 AM
File
1-s2.0-S2211124720302734-main_...
Publication funded by an institution
Licence
Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License